Upcoming sickle cell gene therapies cost effective at $2 million, says ICER
Pharmaceutical Technology
APRIL 13, 2023
Although the findings in the report are only preliminary, they shed light at the considerations behind the high price tags of gene therapies. Bluebird already uses a lentiviral vector in its approved gene therapy for beta-thalassemia called Zynteglo. Also known as lovo-cel, bluebird bio’s product is a lentiviral gene therapy.
Let's personalize your content